High-dose aprotinin effectively reduces blood loss during on-pump coronary artery bypass grafting with bivalirudin anticoagulation.
Koster
Andreas
A
Department of Anesthesia, Deutsches Herzzentrum, Berlin, Germany. koster@dhzb.de
Buz
Semih
S
Krabatsch
Thomas
T
Dehmel
Frank
F
Kuppe
Hermann
H
Hetzer
Roland
R
Aronson
Solomon
S
Dyke
Cornelius M
CM
D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D007611:Aprotinin / Q000008:administration & dosage*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D001026:Coronary Artery Bypass / Q000379:methods*; D003327:Coronary Disease / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006629:Hirudins / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000008:administration & dosage*; D011336:Probability; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000008:administration & dosage; D012016:Reference Values; D018570:Risk Assessment; D016037:Single-Blind Method; D016019:Survival Analysis; D016896:Treatment Outcome
D000925:Anticoagulants; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D007611:Aprotinin; C074619:bivalirudin